Decreasing the Data Deficit: Improving Post-Market Surveillance in Pharmaceutical Regulation

46 Pages Posted: 10 Dec 2014  

Trudo Lemmens

University of Toronto - Faculty of Law

Shannon Gibson

University of Toronto Faculty of Law

Date Written: May 8, 2014

Abstract

The drug regulatory system is currently largely based on market-entry review of safety and efficacy data and involves only very limited post-market review. Failures in the industry-controlled production of pre-market data and the lack of solid post-market surveillance contribute significantly to highly problematic drug prescription and consumption practices, which have become a very serious public health concern. In this paper, we first discuss how historically grown drug regulations have contributed to the development of industry control over clinical trials, which is one of the key factors behind the limits of pre-market evidence. We then explore some problematic aspects related to the fixation of the drug approval system on pre-market activities, including the lack of good “real-world” evidence on drug safety; the lack of comparative evidence on patient benefit between different drugs; the lack of evidence of the safety and efficacy of off-label prescribed drugs; and the inadequate reporting of adverse drug reactions (ADRs). We argue that a more rigorous and intense post-market surveillance system could counterbalance, at least in part, the distorted situation created by the regulatory reliance on pre-market, industry-produced clinical trials data. In particular, we advocate for improvements to the current ADR reporting system, more explicit requirements for both comparative effectiveness studies and post-market clinical research in real-world settings, the promotion of transparency of pharmaceutical data, and insulating clinical research from industry control.

Keywords: Pharmaceutical Regulation; post-marketing surveillance; adverse drug reactions; transparency; clinical trials

JEL Classification: I18; K23

Suggested Citation

Lemmens, Trudo and Gibson, Shannon, Decreasing the Data Deficit: Improving Post-Market Surveillance in Pharmaceutical Regulation (May 8, 2014). McGill Law Journal 2014; 59(4) 943-988.. Available at SSRN: https://ssrn.com/abstract=2535621

Trudo Lemmens (Contact Author)

University of Toronto - Faculty of Law ( email )

78 and 84 Queen's Park
Toronto, Ontario M5S 2C5
Canada

Shannon Gayle Gibson

University of Toronto Faculty of Law ( email )

Department of Statistical Sciences
Toronto, Ontario M5S 3G8
Canada

HOME PAGE: http://www.linkedin.com/in/shannongibson

Paper statistics

Downloads
90
Rank
236,060
Abstract Views
695